Wiseman A - Search Results

1

Belatacept-based immunosuppression with simultaneous calcineurin inhibitor avoidance and early corticosteroid withdrawal: A prospective, randomized multicenter trial.

Woodle ES, Kaufman DB, Shields AR, Leone J, Matas A, Wiseman A, West-Thielke P, Sa T, King EC, Alloway RR; BEST Study Group. Woodle ES, et al. Among authors: wiseman a. Am J Transplant. 2020 Apr;20(4):1039-1055. doi: 10.1111/ajt.15688. Epub 2020 Feb 6. Am J Transplant. 2020. PMID: 31680394 Free article. Clinical Trial.

2

Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity.

Gibney EM, Parikh CR, Jani A, Fischer MJ, Collier D, Wiseman AC. Gibney EM, et al. Among authors: wiseman ac. Am J Transplant. 2004 Dec;4(12):2027-31. doi: 10.1111/j.1600-6143.2004.00605.x. Am J Transplant. 2004. PMID: 15575905 Free article.

3

Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group. Gaber AO, et al. Transplantation. 2008 Nov 15;86(9):1187-95. doi: 10.1097/TP.0b013e318187bab0. Transplantation. 2008. PMID: 19005398 Clinical Trial.

4

Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.

Gralla J, Wiseman AC. Gralla J, et al. Transplantation. 2009 Jun 15;87(11):1712-9. doi: 10.1097/TP.0b013e3181a60431. Transplantation. 2009. PMID: 19502965

5

Corticosteroid elimination in simultaneous liver-kidney transplantation recipients.

Weber NK, Wiseman AC, Trotter JF. Weber NK, et al. Clin Transplant. 2009 Nov-Dec;23(6):958-63. doi: 10.1111/j.1399-0012.2009.01051.x. Epub 2009 Aug 2. Clin Transplant. 2009. PMID: 19664017

6

A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin in living-donor kidney transplantation.

Woodle ES, Peddi VR, Tomlanovich S, Mulgaonkar S, Kuo PC; TRIMS Study Investigators. Woodle ES, et al. Clin Transplant. 2010 Jan-Feb;24(1):73-83. doi: 10.1111/j.1399-0012.2009.01127.x. Epub 2009 Nov 20. Clin Transplant. 2010. PMID: 19930408 Clinical Trial.

7

Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.

Klem P, Cooper JE, Weiss AS, Gralla J, Owen P, Chan L, Wiseman AC. Klem P, et al. Transplantation. 2009 Oct 15;88(7):891-6. doi: 10.1097/TP.0b013e3181b6f38c. Transplantation. 2009. PMID: 19935460

8

YSPSL (rPSGL-Ig) for improvement of early renal allograft function: a double-blind, placebo-controlled, multi-center Phase IIa study.

Gaber AO, Mulgaonkar S, Kahan BD, Woodle ES, Alloway R, Bajjoka I, Jensik S, Klintmalm GB, Patton PR, Wiseman A, Lipshutz G, Kupiec-Weglinski J, Gaber LW, Katz E, Irish W, Squiers EC, Hemmerich S. Gaber AO, et al. Among authors: wiseman a. Clin Transplant. 2011 Jul-Aug;25(4):523-33. doi: 10.1111/j.1399-0012.2010.01295.x. Epub 2010 Jun 22. Clin Transplant. 2011. PMID: 20573162 Clinical Trial.

9

The impact of IL2ra induction therapy in kidney transplantation using tacrolimus- and mycophenolate-based immunosuppression.

Gralla J, Wiseman AC. Gralla J, et al. Transplantation. 2010 Sep 27;90(6):639-44. doi: 10.1097/TP.0b013e3181ea6788. Transplantation. 2010. PMID: 20595929

10

Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes.

Cooper JE, Gralla J, Cagle L, Goldberg R, Chan L, Wiseman AC. Cooper JE, et al. Transplantation. 2011 May 27;91(10):1103-9. doi: 10.1097/TP.0b013e3182139da1. Transplantation. 2011. PMID: 21403588

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

450 results

Search Page